See more : Conifex Timber Inc. (CFXTF) Income Statement Analysis – Financial Results
Complete financial analysis of Third Harmonic Bio, Inc. (THRD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Third Harmonic Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Unibel S.A. (UNBL.PA) Income Statement Analysis – Financial Results
- Zhejiang Juli Culture Development Co.,Ltd. (002247.SZ) Income Statement Analysis – Financial Results
- Madhucon Projects Limited (MADHUCON.BO) Income Statement Analysis – Financial Results
- Ionis Pharmaceuticals, Inc. (IONS) Income Statement Analysis – Financial Results
- Qeeka Home (Cayman) Inc. (1739.HK) Income Statement Analysis – Financial Results
Third Harmonic Bio, Inc. (THRD)
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.00K | 38.00K | 0.00 | 0.00 |
| Gross Profit | -35.00K | -38.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.96M | 24.41M | 15.75M | 9.95M |
| General & Administrative | 19.99M | 13.30M | 3.26M | 1.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.99M | 13.30M | 3.26M | 1.17M |
| Other Expenses | 0.00 | 2.55M | -10.61M | -1.69M |
| Operating Expenses | 43.92M | 37.71M | 19.00M | 11.12M |
| Cost & Expenses | 43.95M | 37.71M | 19.00M | 11.12M |
| Interest Income | 13.13M | 2.55K | 5.00 | 0.00 |
| Interest Expense | 0.00 | 2.55M | 0.00 | 0.00 |
| Depreciation & Amortization | 35.00K | 38.00K | 19.00M | 11.12M |
| EBITDA | -30.79M | -35.12M | -10.61M | -1.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.95M | -37.71M | -19.00M | -11.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.13M | 2.55M | -10.61M | -1.69M |
| Income Before Tax | -30.82M | -35.16M | -29.61M | -12.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.55M | -19.00K | -1.00K |
| Net Income | -30.82M | -37.71M | -29.61M | -12.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.96 | -0.77 | -0.33 |
| EPS Diluted | -0.78 | -0.96 | -0.77 | -0.33 |
| Weighted Avg Shares Out | 39.65M | 39.38M | 38.69M | 38.69M |
| Weighted Avg Shares Out (Dil) | 39.65M | 39.38M | 38.69M | 38.69M |
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Third Harmonic Bio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Third Harmonic Bio,...
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile
Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Why Is Third Harmonic Bio (THRD) Stock Down 75% Today?
Long-term investors of Third Harmonic Bio (NASDAQ: THRD ) are feeling some discomfort today, to put it mildly. This morning, THRD stock is losing the majority of its value because the company halted a clinical trial.
Third Harmonic's stock falls 75% after discontinuing clinical trial
Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common inflammatory skin condition, over safety concerns. Third Harmonic...
Third Harmonic Scores Most Successful Biotech IPO in Months
A partner in a large Cambridge, Massachusetts-based venture capital firm is confident that investors' appetite for biotech startups will begin to pick up in the fall.
Is Third Harmonic Bio (THRD) Stock the Next Red-Hot IPO?
One of the hottest recent biotech initial public offerings belongs to Third Harmonic (NASDAQ: THRD ). Today, this early stage biotech company focused on developing a drug for allergic and inflammatory diseases went public.
Third Harmonic Bio stock opens more than 20% above IPO price
Third Harmonic Bio Inc. THRD, +22.50% received a warm Wall Street welcome Thursday, as the biotechnology company's stock opened 20.6% above the initial public offering price. The company, which specializes in allergic and inflammatory diseases, said early Thursday that its...
TF Financial Corporation Shareholders Approve Merger with National Penn Bancshares, Inc.
ALLENTOWN, Pa. & NEWTOWN, Pa.--(BUSINESS WIRE)--National Penn Bancshares, Inc. (NASDAQ: NPBC) (“National Penn”) and TF Financial Corporation (NASDAQ: THRD) (“TF Financial”) announced that at a special meeting held today, the shareholders of TF Financial approved the Agreement and Plan of...
Source: https://incomestatements.info
Category: Stock Reports